Jordan Roberts, MD
Family Medicine · Holladay, UTNPI 1588043871
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Lucid Diagnostics Inc. at 51.5% of the total. Reporting peaked in 2022 at $6,374 and has fallen 74.8% since, to $1,607 in 2025. Among family medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $37.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lucid Diagnostics Inc.$8K
- AbbVie$683
- Boehringer Ingelheim$635
- Johnson & Johnson$551
- Amgen$543
- Lilly USA, LLC$462
- plus $4K from 50 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lucid Diagnostics Inc.$500
What the payments were for
- Consulting fees$3,41323%
- Travel & lodging$4,15827%
- Food & beverage$7,57150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ESOCHECK CCD CELL COLLECTION DEVICE$5,471
- Yeztugo$122
- SPRAVATO$122
How this compares
$15,141 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 14 | $187,165 |
| EliquisApixaban | 67 | $82,953 |
| OzempicSemaglutide | 65 | $71,693 |
| FarxigaDapagliflozin Propanediol | 40 | $52,464 |
| MounjaroTirzepatide | 35 | $41,994 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $23,071 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $20,649 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $12,652 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 15 | $10,604 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,345 |
| Pregabalin | 35 | $3,477 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,275 |
| Omeprazole | 137 | $3,238 |
| LantusInsulin Glargine,hum.Rec.Anlog | 20 | $3,176 |
| Gabapentin | 155 | $2,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $74 | $187,16514 claims |
| PfizerEliquis | $249 | $82,95367 claims |
| Novo NordiskOzempic | $198 | $71,69365 claims |
| AstraZenecaFarxiga, Symbicort | $406 | $55,73952 claims |
| Lilly USA, LLCMounjaro | $462 | $41,99435 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $298 | $26,24744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 928 family medicine providers in Utah.
Other family medicine in Holladay
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Scott EricksonBountiful$101K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
- John TemplemanProvo$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.